Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss

 
• By Ayisha Sharma

Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.  

open road in desert
The Road To Success Is Clear For Tiragolumab Despite A Short-Term Setback • Source: Alamy

More from Clinical Trials

More from R&D